On May 28, 2023, the Board of Directors of Rain Oncology Inc. approved a restructuring plan in connection with a reprioritization of the Company's clinical strategy designed to optimize Company resources. As previously announced, the Company intends to suspend enrollment in its Phase 2 MANTRA-2 basket trial and terminate plans to initiate its Phase 1/2 MANTRA-4 combination trial. The Company expects to continue to evaluate outcomes from its MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma, with data and findings expected to be presented at a medical conference in the fourth quarter of fiscal 2023.